Medical Strategy & Product Development

Ataraxis AI is a precision medicine company dedicated to transforming cancer diagnostics and patient outcomes through the power of artificial intelligence. The company was founded by Jan Witowski, MD, PhD, and Krzysztof Geras, PhD, and spun out of New York University in 2023. Ataraxis AI is focused on addressing previously unsolvable challenges in cancer prognosis and treatment selection by leveraging cutting-edge foundation models and multi-modal data. The company's mission is to empower physicians with advanced tools that can accurately pinpoint the most effective treatments, thereby enhancing patient care and driving superior health outcomes. By integrating information from multiple digital data modalities, Ataraxis systems discover novel clinical, morphological, and molecular features of patients and their diseases, capturing the heterogeneity of cancer beyond what a single data type can provide.

The core of Ataraxis AI's technology is Kestrel, a state-of-the-art foundation AI model for digital pathology. Trained on hundreds of millions of pan-cancer pathology slide images, Kestrel extracts new information about tumor morphology that strongly correlates with patient outcomes and treatment response. This proprietary technology allows the company to analyze multi-modal patient data to assess disease aggressiveness, predict the risk of cancer recurrence or death, and determine how various treatment options might benefit different patients. The company's first clinically validated product, Ataraxis Breast, is the world's first AI-native prognostic and predictive test for breast cancer. Validated using data from over 8,000 patients across 15 institutions, Ataraxis Breast has demonstrated greater accuracy than standard-of-care genomic assays in identifying high- and low-risk patients. Unlike traditional molecular tests, Ataraxis delivers results within 24 hours without exhausting valuable tissue, positioning itself at the forefront of a new, more efficient, and cost-effective era of AI-driven precision medicine.